Global Presence
At MSN Laboratories, our capabilities in biotechnology business includes, development and manufacturing of bio-therapeutics (Biologics) and fermentation-based small molecule APIs. Our state-of-the-art facilities reflect our commitment to innovation, quality, and sustainability.
Spanning an impressive 45,000 square meters, our Biologics facility is dedicated to the research, development, and manufacturing of advanced monoclonal antibodies and protein therapeutics.
Bioreactor Range & Downstream Processing
Equipped with single-use bioreactors ranging from 50 L to 2.1 KL for scalable production and supported by advanced downstream systems ensuring high-quality drug substance manufacturing.
Simultaneous Multi-Product Capability
Manufacturing suites designed to enable parallel production of multiple biologics, serving both MSN’s internal pipeline and global contract manufacturing needs.
R&D Facility & Analytical Characterization
A 7,500 sq. m. R&D center equipped with bioreactors of varied capacities, downstream suites, and a state-of-the-art analytical characterization unit for process development and optimization.
Experienced Global Team & Quality Systems
Led by a team with hands-on global experience in biologics development and commercialization, backed by robust quality systems aligned with international regulatory expectations.
State-of-the-Art Manufacturing Suites
20,000 sq. m. facility designed for cell culture–based manufacturing of biotherapeutics, featuring advanced infrastructure built to global standards.
Microbial Fermentation: Integrating Expertise and Innovation
Integrated within our existing API manufacturing facility, the microbial fermentation unit boasts a robust infrastructure to meet the growing demands of fermentation-based APIs
Fermentation Capacity
Exceeds 50 KL, with fermenters ranging from 50 litres to 25 KL, ensuring flexible and scalable production
Future Expansion
Large-volume fermenters with a capacity of 100 KL to support the continuous production of high-volume fermentation products
Specialized Expertise
The team specializes in bacterial, yeast, and fungal fermentation, catering to the production of:
This integrated approach strengthens MSN’s capabilities in delivering high-quality fermentation-based APIs to meet global healthcare needs.
Driving Innovation and Accessibility
MSN Laboratories’ entry into biotechnology reflects our unwavering commitment to accessible healthcare, innovation, and environmental sustainability. By combining cutting-edge technology with industry expertise, we aim to transform the biotech landscape and deliver impactful solutions to patients worldwide.
